Bioanalytical Method Validation
Bioanalytical method validation is the evidence that an assay measuring a drug (and its metabolites) in a biological matrix — plasma, serum, blood, urine — produces reliable, reproducible results across the concentration range it will be used for. The pharmacokinetic and toxicokinetic conclusions of a clinical or nonclinical study are only as trustworthy as the assay that generated the concentrations, so bioanalysis sits at the intersection of GLP and GCLP and is one of the most tightly specified measurement activities in drug development. A validated method is the precondition for believing any exposure number derived from it.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 22 LINKSBioanalytical method validation earns the numbers that become PK conclusions: across GCLP and GLP — selectivity, calibration, accuracy, precision, and stability across the real sample journey, confirmed by ISR.
06 · QUALITY MATURITY — BIOANALYTICAL METHOD VALIDATION, REACTIVE TO ADAPTIVE
Assays run without a documented validation; calibration and QC acceptance are improvised and stability is assumed.
A validation report exists, but selectivity and matrix effects are thin and stability is a generic default, not the study timeline.
Selectivity, calibration, accuracy/precision, matrix effects, carry-over, and dilution integrity are validated before study samples are run.
In-study run QCs and incurred sample reanalysis confirm real samples behave like validation samples; failures reject and re-run the batch.
Method performance is monitored across the study lifecycle; stability covers the true sample journey and bioanalysis is integral to data quality by design.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 4 regulatory bodies: ICH, FDA, WHO, ISO.
RECORDS & OBJECTIVE EVIDENCE
- A validation report covering selectivity, calibration, accuracy, precision, and range
- Matrix-effect, recovery, carry-over, and dilution-integrity data
- A stability programme matched to the real sample journey and study timeline
- In-study QC results against defined batch-acceptance criteria
- Incurred sample reanalysis results and their acceptance evaluation
COMMON INSPECTION FINDINGS
- Study samples analysed against a method with no completed validation
- Stability validated to a generic default shorter than actual sample storage
- Matrix effects or selectivity uncharacterised for the real study matrix
- Runs accepted despite failing QC acceptance criteria
- Incurred sample reanalysis not performed, or its failures not investigated
Why bioanalysis is validated so rigorously
The concentrations a bioanalytical method produces become the pharmacokinetic parameters — Cmax, AUC, half-life — on which dosing, bioequivalence, and safety conclusions rest. An assay that is biased, imprecise, or susceptible to matrix interference propagates that error directly into those conclusions. The regulatory frameworks for bioanalytical method validation exist because the measurement is remote from the biology it informs: nobody sees the drug, only the number the assay returns, so the number must be earned.
Bioanalytical validation is governed by dedicated guidance and, increasingly, by the harmonised ICH bioanalytical method validation guideline, applied within the GLP quality system for nonclinical studies and GCLP-aligned expectations for clinical sample analysis. The through-line is the same: define the parameters the method must satisfy, demonstrate they are met before study samples are analysed, and monitor performance while they are.
The core validation parameters
A full validation characterises a defined set of parameters. Selectivity confirms the method distinguishes the analyte from matrix components, metabolites, and co-medications. The calibration curve establishes the relationship between response and concentration across the range, anchored by a lower limit of quantitation with defined accuracy and precision. Accuracy (closeness to true value) and precision (reproducibility) are demonstrated within-run and between-run at multiple concentration levels spanning the range.
Beyond these, validation addresses matrix effects and recovery (especially for mass-spectrometry methods, where ion suppression can silently bias results), carry-over (contamination from a high sample into the next), dilution integrity (so samples above the range can be diluted and still measured accurately), and reproducibility. SPEQ synthesis: the parameters are not independent boxes — a beautiful calibration curve means little if selectivity is weak or matrix effects are uncharacterised, because the curve was built in clean matrix and the study samples are not clean.
Stability — the parameter most often underestimated
Study samples are collected, shipped, stored, thawed, and analysed over time, and the analyte must survive all of it. Bioanalytical validation therefore demonstrates stability across the conditions samples will actually experience: bench-top (short-term at processing temperature), freeze-thaw cycles, long-term frozen storage for at least as long as samples will be stored, stock-solution stability, and post-preparative (autosampler) stability. If the analyte degrades under a condition samples encounter, the reported concentrations are systematically low and the study is compromised.
The rule that binds this together is that stability must cover the real sample journey — the long-term storage period validated must equal or exceed the longest time any study sample is held before analysis. A method validated for three months of frozen storage cannot support samples analysed after six. This is why stability is planned around the study timeline, not a generic default, and why late-analysed samples are a recurring source of findings.
From validation to in-study performance
Validation proves the method works before study samples are analysed; in-study quality control proves it kept working while they were. Each analytical run includes quality-control samples at low, medium, and high concentrations, and defined acceptance criteria decide whether the run is accepted — a common convention requires a set proportion of QC results to fall within a defined tolerance of nominal, the batch acceptance criterion for QC samples. A run failing its QC criteria is rejected and re-analysed, so acceptable study data always sits inside demonstrated in-run performance.
Incurred sample reanalysis (ISR) is the check that validation in spiked samples translates to real ones: a subset of study samples is re-analysed in separate runs and the results compared, testing whether real biological samples — with their metabolites and variability — behave like the validation samples. Together, run QCs and ISR close the gap between "the method validated" and "the method actually measured these study samples reliably," which is the claim the pharmacokinetics ultimately depends on.
FREQUENTLY ASKED
What parameters does bioanalytical method validation cover?
Selectivity, calibration curve and range (with a defined lower limit of quantitation), within-run and between-run accuracy and precision at multiple levels, matrix effects and recovery, carry-over, dilution integrity, reproducibility, and a full stability programme. Each is demonstrated before study samples are analysed, and in-study quality controls confirm performance is maintained during analysis.
Why is stability so important in bioanalysis?
Because study samples are collected, shipped, stored, freeze-thawed, and analysed over time, and if the analyte degrades under any condition the samples experience, the reported concentrations are systematically low. Validation must demonstrate stability across the real sample journey, and the validated long-term storage period must equal or exceed the longest time any study sample is held before analysis.
What is incurred sample reanalysis (ISR)?
ISR re-analyses a subset of actual study samples in separate runs and compares the results, testing whether real biological samples — with their metabolites and variability — behave like the spiked validation samples. It bridges the gap between a method validating in prepared samples and the method reliably measuring genuine study samples.